Companies · Biotechnology

Adjuvance Technologies Inc.

Lincoln · Biotechnology

Diligence memoA one-page analyst read on Adjuvance Technologies Inc. — recommendation, valuation, rhythm, risks.
$13.4M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 40%
Sector rank · raised
Series A
Latest stage · inferred · Thu Aug 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Adjuvance Technologies Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.13× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Adjuvance Technologies Inc. is one of 4293 Biotechnology companies tracked from Lincoln. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
28
Investors (latest)
2019-08-29
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2015-08-06 Raised $2.7M (real) Modeled valuation $121M (est)$2.7M$121MSeed2015Pre-Seed · 2015-08-06 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2015Series A · 2019-08-29 Raised $11M (real) Modeled valuation $385M (est)$11M$385MSeries A2019Series A · 2019-08-29 Raised $11M (real) Modeled valuation $385M (est)$11M$385MSeries A2019+$1.0M+$11M+$11MCumulative $25M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.7M · 2015
Bridge · Seed-stage$1.0M · 2015smaller follow-on
Series A$10.7M · 2019
Series A extension$10.7M · 2019

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$385.3M
Base estimate est.
$11.6M
Conservative case
$2.1B
Upside case
$48.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $120.7M · 2015-08-062015Pre-Seed · modeled $55.2M · 2015-08-06Series A · modeled $385.3M · 2019-08-29Series A · modeled $385.3M · 2019-08-292019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
6.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$3.3M/yr
Capital velocity
10.9 yr
On record since
2015
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.9× above median
This company$13.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.0× above median
This company$10.7M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 6.0× above median
This company$385.3M
Sector median$64.2M

Raised more than 61% of sector peers (real $). Modeled value above 80% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #18 of 216.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Adjuvance Technologies Inc. (this company) Raised $13.4M · modeled $385.3M (est)Adjuvance Technologies Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Adjuvance Technologies Inc. this companySeries A$13.4M$385.3M2.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.7M2015-08-06$13.6M$120.7M90%
Pre-Seed$1.0M2015-08-06$5.6M$55.2M85%
Series A$10.7M2019-08-29$48.4M$385.3M90%
Series A$10.7M2019-08-29$48.4M$385.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.7M2015-08-06
    • First recorded raise — entered as Seed.
    • 15 investors on this round.
  2. Pre-Seed$1.0M2015-08-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.7× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  3. Series A$10.7M2019-08-29
    • Raised again after 49 mo — slower than the ~14 mo sector norm.
    • Round 10.7× larger than the prior — scaling up.
    • 28 investors on this round.
  4. Series A$10.7M2019-08-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 28 investors on this round.
Intelligence
2021 ~Q1
Modeled next raise · ~16mo cadence
$10.7M
Modeled next size est.range $10.7M$17.1M
1.0×
Last step-up
$3.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Isaac Cheng8 other2019-08
Jeffrey Gardner3 other2015-08
John Gallo1 other2015-08
Ken Kelley1 other2019-08
Christopher Frigon2015-08
Govind Ragupathi2015-08
Gregory Poland2015-08
J. Tyler Martin2019-08
Mary Gin2015-08
Phil Livingston2015-08
Stephen Dilly2019-08
Tyler Martin2015-08
Registry & provenance

Adjuvance Technologies Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1652786
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Meissa Vaccines IncBiotechnologySeries A$15.2M$503.1Mnetwork1 shared operator · same sector · same stage
Revitope Oncology, Inc.BiotechnologySeries A$13.4M$296.4Msame sector · same stage
BioTrove, Inc.BiotechnologySeries A$13.3M$481.3Msame sector · same stage
BrainXell, Inc.BiotechnologySeries A$13.2M$274.5Msame sector · same stage
Overture Life, Inc.BiotechnologySeries A$13.6M$491.7Msame sector · same stage
Curie Co. Inc.BiotechnologySeries A$13.1M$390.0Msame sector · same stage
V ClinBio LLCBiotechnologySeries A$13.7M$352.5Msame sector · same stage
Vibe Bioscience CorpBiotechnologySeries A$13.7M$476.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Advaxis, Inc.BiotechnologySeries A$3.2M89%
ADRX, Inc.BiotechnologySeries A$177.3M86%
Adela, Inc.BiotechnologySeries C$156.3M85%
Adolore Biotherapeutics, Inc.BiotechnologySeed$6.9M85%
Neurovance, Inc.BiotechnologySeries A$20.0M85%
Rejuveron Life Sciences AGBiotechnologySeed$43.8M84%
Rejuvitas, Inc.BiotechnologySeries A$63.6M84%
Biogix, Inc.BiotechnologySeed$88.8M83%
Frequently asked
How much funding has Adjuvance Technologies Inc. raised?
Adjuvance Technologies Inc. has raised approximately $13.4M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Adjuvance Technologies Inc.'s estimated valuation?
Provath's modeled valuation for Adjuvance Technologies Inc. is approximately $385.3M (modeled range $11.6M–$2.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Adjuvance Technologies Inc. at?
Adjuvance Technologies Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Aug 29.
What does Adjuvance Technologies Inc. do and where is it based?
Adjuvance Technologies Inc. operates in the Biotechnology sector, based in Lincoln.
Explore related

See where Adjuvance Technologies Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Adjuvance Technologies Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.